Pharmacokinetic endpoints have always been important, but recent U.S. Food and Drug Administration guidelines, increase the need for dose optimization early in clinical trial development, especially around oncology research. Finding an optimal dose and providing patients with an efficacious dose with minimal safety hazards is essential to the work Catalyst does.
Watch Craig McIlloney, Senior Vice President, Catalyst Flex, and Lydia King, Director of Biostatistics, Catalyst Oncology, discuss the significance of pharmacokinetic (PK) data in advancing oncology therapeutics and how Catalyst can support this vital area of early development.
Learn how Catalyst’s comprehensive PK services are tailored to address specific needs and help to ensure that each project contributes effectively to the development of cancer treatments.
